Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-CD20 agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.

Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-TNF? agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of the treatment in said patient.

Abstract: The disclosure relates to a method for estimating the effectiveness of treatment with a T-lymphocyte cell co-stimulation modulator agent in a patient with rheumatoid arthritis and who has had an inadequate response to prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said modulator agent is a treatment that will engender a beneficial response for said patient. The disclosure also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data concerning the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.

Abstract: The present invention provides a method of measuring the levels of APRIL in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as RA, predicting the future severity of the disease, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with APRIL antagonists, either singly or in combination with other immune suppressive drugs.

Abstract: The present invention provides a method of measuring the levels of APRIL in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as RA, predicting the future severity of the disease, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with APRIL antagonists, either singly or in combination with other immune suppressive drugs.